Leukemia News

More than a year into the COVID-19 pandemic, new information emerges daily about the virus and its effects on various vulnerable populations.

Chimeric antigen receptor T-cell therapy has been heralded as a transformative addition to the cancer treatment armamentarium.

Younger patients who experienced disease progression after CD19-directed chimeric antigen receptor T-cell therapy had significantly shorter OS than those who did not relapse, according to results presented at TCT Meetings Digital Experience.

Poly(ADP-ribose) polymerase, or PARP, inhibitors appeared associated with increased risk for secondary myelodysplastic syndrome and acute myeloid leukemia compared with placebo among patients with cancer, according to study results.

Total body irradiation plus etoposide improved OS and appeared to reduce risk for relapse among children with high-risk acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant, study results showed.

An investigational chimeric antigen receptor T-cell therapy appeared safe and demonstrated antitumor activity among patients with relapsed or refractory B-cell malignancies, according to results presented at TCT Meetings Digital Experience.

Children and young adults with acute lymphoblastic leukemia who received higher doses of tisagenlecleucel achieved significantly longer OS and RFS, according to study results presented at TCT Meetings Digital Experience.

The FDA granted breakthrough therapy designation to asciminib for treatment of certain patients with chronic myeloid leukemia.

Younger Black patients who received tisagenlecleucel for acute lymphoblastic leukemia had significantly poorer outcomes than those of other races or ethnicities, according to results presented at TCT Meetings Digital Experience.

The FDA cleared an investigational new drug application for KITE-222, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory acute myeloid leukemia, according to the agent’s manufacturer.